Atlas Trials

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Clinical trial NCT00064246 · COMPLETED

Trial details

NCT number
NCT00064246
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Post-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström Macroglobulinemia
Start date
2003-07-01
Primary completion
2004-09-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.